Cerebrospinal Fluid and Plasma (1→3)-β-d-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous Candida Meningoencephalitis

Documenti analoghi

• The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous Candida Meningoencephalitis: Implications for Echinocandin Therapy in Neonates
  di: Hope, William W., et al.
  Pubblicazione: (2008)
• Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits
  di: Petraitiene, Ruta, et al.
  Pubblicazione: (2021)
• Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis
  di: Petraitis, Vidmantas, et al.
  Pubblicazione: (2019)
• The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-d-Glucan, and Consequences of Delayed Antifungal Therapy
  di: Hope, William W., et al.
  Pubblicazione: (2010)
• Efficacy, Plasma Pharmacokinetics, and Safety of Icofungipen, an Inhibitor of Candida Isoleucyl-tRNA Synthetase, in Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits
  di: Petraitiene, Ruta, et al.
  Pubblicazione: (2005)